A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-024

Status: Open to Accrual

Learn more:

• clinicaltrials.gov: #NCT03090165
• See Study Locations on Big Ten CRC Website

Study Contact: studies@hoosiercancer.org; (317) 921-2050.